Screener
Charles River Laboratories CRL U.S. — Total Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Service revenue | $808,287 | $840,836 | $1,606,439 | $1,638,759 |
| Product revenue | 195,791 | 191,299 | 393,469 | 377,544 |
| Total revenue | 1,004,078 | 1,032,135 | 1,999,908 | 2,016,303 |
| Costs and expenses | ||||
| Cost of services provided (excluding amortization of intangible assets) | 552,007 | 584,876 | 1,160,914 | 1,162,304 |
| Cost of products sold (excluding amortization of intangible assets) | 88,697 | 90,192 | 180,956 | 179,200 |
| Selling, general and administrative | 228,897 | 191,549 | 388,319 | 369,348 |
| Amortization of intangible assets | 14,589 | 65,384 | 29,934 | 130,648 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's U.S. — total revenue?
- Charles River Laboratories (CRL) reported U.S. — total revenue of $539.86M in Q2 2026.
- How has Charles River Laboratories's U.S. — total revenue changed year-over-year?
- Charles River Laboratories's U.S. — total revenue decreased by 1.8% year-over-year, from $549.86M to $539.86M.
- What is the long-term trend for Charles River Laboratories's U.S. — total revenue?
- Over 4 years (2021 to 2025), Charles River Laboratories's U.S. — total revenue has grown at a 2.6% compound annual growth rate (CAGR), from $1.93B to $2.14B.
- What does U.S. — total revenue mean?
- This metric represents the total gross income generated by the company's operations within the United States geographic segment. It reflects the demand for research models, services, and laboratory support provided to domestic clients, including pharmaceutical and biotechnology firms. Tracking this figure helps investors assess the company's market penetration and revenue stability within its primary domestic market.
Ask your AI about Charles River Laboratories's u.s. — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude